Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

Access Activity

Overview / Abstract:

Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents hold promise for patients who have relapsed from or become refractory to previous therapies"but these additional options make navigating treatment significantly more challenging for clinicians. Furthermore, many current and emerging BCMA-targeted therapies are associated with unique adverse events that may be unfamiliar to clinicians.

In this virtual Q&A activity, experts provide evidence-based responses to challenging questions on incorporating new and emerging BCMA-targeted therapies that achieve durable remission for RRMM patients and minimizing the toxicities associated with their use. The activity includes animated videos demonstrating the mechanisms of action (MOAs) of several BCMA-targeted agents.

Educational Objectives
Upon completion of this activity, participants should be better able to:
• Distinguish between the efficacies, safety profiles, and MOAs of current and emerging BCMA-targeted agents for MM patients who have relapsed from or are resistant to multiple prior therapies
• Summarize the toxicity profiles of BCMA-targeted agents used to treat RRMM, particularly with respect to the immunotherapies most associated with cytokine release syndrome (CRS) and immune effector cell"associated neurotoxicity syndrome (ICANS)
• Optimize selection and sequencing of the most appropriate BCMA-targeted therapies for patients with RRMM


Mar 11, 2025


Nurse Practitioner , Physician CME, Physician Assistant CME



Credits / Hours

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians. Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Presenters / Authors / Faculty

Eden Biltibo, MD, MS
Assistant Professor
Vanderbilt University Medical Center
Nashville, Tennessee

Noopur S. Raje, MD
Massachusetts General Hospital
Boston, Massachusetts

Sponsors / Supporters / Grant Providers

Support for this activity is provided through an educational grant from Bristol Myers Squibb.

Keywords / Search Terms

RedMedEd RedMedEd, MMRF, MM, multiple myeloma, multiple myeloma research foundation, tests, risk, relapsed/refractory, relapsed, refractory, outcomes, RRMM, treatment, initial therapies, therapies, treatment, clinicians, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy, Free CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map